Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launched these strengths of lenalidomide.

• GK Energy Rallies on Rs 235.92 Crore Solar Pump Order
• Cupid Hits Fresh 52-Week High on Rs 128 Crore Block Deal
• Ather Energy Slips Despite $200 Million Fundraise Buzz
• Shyam Metalics Slips Even as Q1 Volumes Surge
• Unihealth Hospitals Shares Hit 5% Upper Circuit on Plans to Raise Stake 

In the above strengths of lenalidomide, capsules are prescribed in adults to treat multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.